Wide Ranks

ALZN

Alzamend Neuro, Inc.

1.26

Top Statistics
Market Cap 5 M Forward PE -0.3614 Revenue Growth 0.00 %
Current Ratio 0.49 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5090 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.3070 Total Debt
Total Debt To Equity Current Ratio 0.49 Book Value Per Share -1.41
All Measures
Short Ratio 54.00 % Message Board Id finmb_367712111 Shares Short Prior Month 228357
City Atlanta Uuid b0577044-824a-3769-9c91-1a7bb4b1f2b7 Previous Close 1.28
First Trade Date Epoch Utc 1 B Book Value -1.41 Beta -0.0380
Volume 119498 Last Split Date 1 B Fifty Two Week Low 1.25
Total Cash Per Share 0.3070 Shares Short Previous Month Date 1 B Target Median Price 35.00
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 35.00
Net Income To Common -7394391 Short Percent Of Float 0.0338 Implied Shares Outstanding 4 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 141150
Average Volume10days 141150 Total Cash 1 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0455 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.28 Target Low Price 35.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.56 Open 1.27
Free Cashflow -3355994 State GA Dividend Yield 0.00 %
Return On Assets -2.14 Time Zone Short Name EST Trailing Eps -142.87
Day Low 1.26 Address1 3480 Peachtree Road NE Shares Outstanding 4 M
Price Hint 4 Target High Price 35.00 Website https://www.alzamend.com
52 Week Change -0.8955 Average Volume 279840 Forward Eps -4.55
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 41.40 %
Last Split Factor 1:10 Regular Market Day High 1.30 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 15.06 Day High 1.30
Shares Short 144256 Regular Market Open 1.27 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0322
Operating Cashflow -6027535 Currency USD Time Zone Full Name America/New_York
Market Cap 5 M Is_nasdaq_100 False Zip 30326
Quote Type EQUITY Industry Biotechnology Long Name Alzamend Neuro, Inc.
Regular Market Day Low 1.26 Held Percent Institutions 0.0094 Current Price 1.26
Address2 Second Floor, Suite 103 Enterprise To Ebitda -0.5090 Financial Currency USD
Current Ratio 0.49 Industry Disp Biotechnology Number Of Analyst Opinions 1
Country United States Float Shares 3 M Two Hundred Day Average 4.79
Enterprise Value 3 M Forward PE -0.3614 Regular Market Volume 119498
Ebitda -7323379 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.

Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.